SLC5A2 and type 2 diabetes mellitus: With the emergence of new groups of antidiabetic drugs, such as glucagon-like peptide 1 receptor agonists (GLP-1ra) and sodium-glucose cotransporter-2 inhibitors (SGLT2-in), which have significant cardio- and renal-protective effects, the pharmacological treatment of T2D has begun to undergo revolutionary changes [13].